{
    "ticker": "FBT",
    "name": "Forte Biosciences, Inc.",
    "description": "Forte Biosciences, Inc. is an innovative biotechnology company focused on developing novel therapies for patients with serious dermatological conditions. Founded in 2014, Forte is committed to leveraging its proprietary platform to advance the treatment of skin diseases through cutting-edge research and development. The company's lead product candidates, which include treatments for conditions such as atopic dermatitis and vitiligo, are designed to address the underlying causes of these diseases, offering hope for improved patient outcomes. Forte aims to revolutionize the dermatology space by utilizing its extensive knowledge in immunology and cell biology to create safer and more effective therapeutic options. With a team of experienced scientists and industry professionals, Forte is dedicated to bringing transformative solutions to the market that enhance the quality of life for patients suffering from chronic skin disorders. The company is actively engaged in clinical trials to evaluate the efficacy and safety of its products, with the goal of obtaining regulatory approvals to bring these innovative therapies to patients in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2014",
    "website": "https://fortebio.com",
    "ceo": "Gina G. C. P. A. D. L. S. B. C.",
    "social_media": {
        "twitter": "https://twitter.com/ForteBiosci",
        "linkedin": "https://www.linkedin.com/company/forte-biosciences/"
    },
    "investor_relations": "https://investors.fortebio.com",
    "key_executives": [
        {
            "name": "Gina G. C. P. A. D. L. S. B. C.",
            "position": "CEO"
        },
        {
            "name": "John Doe",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "FB-101",
                "FB-102"
            ]
        }
    ],
    "seo": {
        "meta_title": "Forte Biosciences, Inc. | Innovative Dermatology Solutions",
        "meta_description": "Learn about Forte Biosciences, Inc., a leader in biotechnology focused on developing innovative therapies for dermatological conditions. Discover our mission and product pipeline.",
        "keywords": [
            "Forte Biosciences",
            "Biotechnology",
            "Dermatology",
            "Atopic Dermatitis",
            "Vitiligo"
        ]
    },
    "faq": [
        {
            "question": "What does Forte Biosciences specialize in?",
            "answer": "Forte Biosciences specializes in developing innovative therapies for serious dermatological conditions."
        },
        {
            "question": "Who is the CEO of Forte Biosciences?",
            "answer": "Gina G. C. P. A. D. L. S. B. C. is the CEO of Forte Biosciences, Inc."
        },
        {
            "question": "Where is Forte Biosciences headquartered?",
            "answer": "Forte Biosciences is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What are Forte's main products?",
            "answer": "Forte's main product candidates include FB-101 and FB-102, aimed at treating atopic dermatitis and vitiligo."
        },
        {
            "question": "When was Forte Biosciences founded?",
            "answer": "Forte Biosciences was founded in 2014."
        }
    ],
    "competitors": [
        "VRTX",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "JNJ",
        "PFE"
    ]
}